TLR2 and neoplasm: Recently, we demonstrated that overexpression of constitutively active GP130 in CAR-T-cells results in a more robust anti-tumor capacity, better persistence and less GVHD (graft-versus-host disease) in solid tumor-derived xenograft models.21 We also showed that the expression of the Toll/interleukin-1 receptor (TIR) domain of Toll-like receptor 2 (TLR2)22 or the DAP10 cytoplasmic domain23 augments the expansion and anti-tumor effects of CAR-T-cells.